13 articles with Imago Biosciences
11/8/2019Pharmaceutical, medtech and biotech companies expand their leadership teams with this week's appointments.
Imago BioSciences Further Expands Executive Team with Appointment of James D. Watson as Chief Business Officer
Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for malignant and life-threatening diseases of the bone marrow, today announced the appointment of James D. Watson as Chief Business Officer.
Imago BioSciences Preliminary Data from Ongoing Phase 2 Study of IMG-7289 for the Treatment of Myelofibrosis to be Presented at the 61st American Society of Hematology Annual Meeting & Exposition
Imago BioSciences, Inc., a clinical-stage biotechnology company focused on the treatment of myeloproliferative neoplasms (MPN) and related bone marrow diseases, announced today that preliminary data from its ongoing Phase 2 study of IMG-7289 (bomedemstat) in patients with myelofibrosis (MF) has been selected for an oral presentation at the American Society of Hematology (ASH) Annual Meeting, on December 9 in Orlando, Florida.
Data Presented At 24ᵗʰ Congress of the European Hematology Association Demonstrates Clinical Safety, Early Efficacy of Imago BioSciences' IMG-7289 in Myelofibrosis Patients
Data Informs Expansion of Study into Phase 2b and Considerations for Clinical Studies of IMG-7289 in Additional Myeloid Diseases
Imago BioSciences to Present First Clinical Data for IMG-7289 At 24th Congress of the European Hematology Association
Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced that an abstract describing clinical data regarding their lysine-specific demethylase (LSD1) inhibitor has been selected for an oral presentation at the 24th Congress of the European Hematology Association (EHA) to be held in Amsterdam, The Netherlands from June 13-16, 2019.
Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced a $40 million Series B financing led by Omega Funds, a leading international investment firm that creates and invests in life sciences companies.
Imago BioSciences Completes Enrollment in Phase 1/2a Study of IMG-7289 in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Imago BioSciences announced today that the Phase 1/2a clinical trial of IMG-7289 for the treatment of high-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) has fully enrolled at 45 patients.
Imago BioSciences Receives FDA Approval of IND Application for the Treatment of Myeloid Malignancies
The IND supports the company's ongoing Phase 1/2 clinical trial of IMG-7289 for myelofibrosis.
Imago Biosciences Doses First Patients In The Phase IIa Portion Of The Study Of IMG-7289 In Acute Myeloid Leukemia And Myelodysplastic Syndrome
Imago Biosciences Enrolls First Patient In Phase 1/2 Study Of IMG-7289 In Acute Myeloid Leukemia And Myelodysplastic Syndrome
Imago Biosciences Announces Preclinical Data On LSD1 Inhibitor At Annual Meeting Of The American Society of Hematology